nach oben

Current Oncology Reports

Erschienen in:

01.11.2018 | Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors

verfasst von: Silvia Schmidtova, Katarina Kalavska, Lucia Kucerova

Erschienen in: Current Oncology Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Testicular germ cell tumors (TGCTs) represent the most common solid tumors affecting young men. Majority of TGCTs respond well to cisplatin-based chemotherapy. However, patients with refractory disease have limited treatment modalities associated with poor prognosis. Here, we discuss the main molecular mechanisms associated with acquired cisplatin resistance in TGCTs and how their understanding might help in the development of new approaches to tackle this clinically relevant problem. We also discuss recent data on the strategies of circumventing the cisplatin resistance from different tumor types potentially efficient also in TGCTs.

Recent Findings

Recent data regarding deregulation of various signaling pathways as well as genetic and epigenetic mechanisms in cisplatin-resistant TGCTs have contributed to understanding of the mechanisms related to the resistance to cisplatin-based chemotherapy in these tumors. Understanding of these mechanisms enabled explaining why majority but not all TGCTs patients are curable with cisplatin-based chemotherapy. Moreover, it could lead to the development of more effective treatment of refractory TGCTs and potentially other solid tumors resistant to platinum-based chemotherapy.

Summary

This review provides additional insights into mechanisms associated with cisplatin resistance in TGCTs, which is a complex phenomenon, and there is a need for novel modalities to overcome it.

Chieffi P. Potential new anticancer molecular targets for the treatment of human testicular seminomas 2011.

Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65(6):1095–106.CrossRefPubMed

Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MAS, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387(10029):1762–74. https://doi.org/10.1016/s0140-6736(15)00991-5.CrossRefPubMed

Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, et al. Testicular non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol. 2010;21(Suppl 5):v147–54. https://doi.org/10.1093/annonc/mdq177.CrossRef

Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, et al. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2012;118(4):981–6. https://doi.org/10.1002/cncr.26375.CrossRefPubMed

Fankhauser CD, Curioni-Fontecedro A, Allmann V, Beyer J, Tischler V, Sulser T, et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer. 2015;113(3):411–3. https://doi.org/10.1038/bjc.2015.244.CrossRefPubMedPubMedCentral

Boublikova L, Buchler T, Stary J, Abrahamova J, Trka J. Molecular biology of testicular germ cell tumors: unique features awaiting clinical application. Crit Rev Oncol Hematol. 2014;89(3):366–85. https://doi.org/10.1016/j.critrevonc.2013.10.001.CrossRefPubMed

Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(6):1551–61. https://doi.org/10.1200/JCO.2002.20.6.1551.CrossRef

Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis. 2011;2:e148. https://doi.org/10.1038/cddis.2011.33.CrossRefPubMedPubMedCentral

10.

Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, et al. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One. 2011;6(4):e19198. https://doi.org/10.1371/journal.pone.0019198.CrossRefPubMedPubMedCentral

11.

Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, et al. Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. Cancer Res. 2013;73(5):1460–9. https://doi.org/10.1158/0008-5472.CAN-12-2876.CrossRefPubMed

12.

Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010;120(10):3594–605. https://doi.org/10.1172/JCI41939.CrossRefPubMedPubMedCentral

13.

Wu YC, Ling TY, Lu SH, Kuo HC, Ho HN, Yeh SD, et al. Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. Cancer Res. 2012;72(19):4963–73. https://doi.org/10.1158/0008-5472.CAN-12-0673.CrossRefPubMed

14.

Cavallo F, Feldman DR, Barchi M. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. Int J Dev Biol. 2013;57(2–4):273–80. https://doi.org/10.1387/ijdb.130135mb.CrossRefPubMed

15.

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–84. https://doi.org/10.1038/nrc2167.CrossRefPubMed

16.

Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer. 2004;110(3):352–61. https://doi.org/10.1002/ijc.20134.CrossRefPubMed

17.

Jacobsen C, Honecker F. Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology. 2015;3(1):111–21. https://doi.org/10.1111/andr.299.CrossRefPubMed

18.

• Awuah SG, Riddell IA, Lippard SJ. Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity. Proc Natl Acad Sci U S A. 2017;114(5):950–5. https://doi.org/10.1073/pnas.1615327114. This study showed that HMGB4, a protein preferentially expressed in testes, plays a major role in sensitizing TGCTs to cisplatin. It specifically blocks repair of the major cisplatin-DNA adducts and potentiates the sensitivity of TGCTs to cisplatin treatment. CrossRef

19.

Mego M, Cierna Z, Svetlovska D, Macak D, Machalekova K, Miskovska V, et al. PARP expression in germ cell tumours. J Clin Pathol. 2013;66(7):607–12. https://doi.org/10.1136/jclinpath-2012-201088.CrossRefPubMed

20.

Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, et al. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One. 2012;7(12):e51563. https://doi.org/10.1371/journal.pone.0051563.CrossRefPubMedPubMedCentral

21.

Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol: Off J Eur Soc Med Oncol. 2011;22(12):2654–60. https://doi.org/10.1093/annonc/mdr026.CrossRef

22.

• Kalavska K, Conteduca V, De Giorgi U, Mego M. Molecular mechanisms of resistance in testicular germ cell tumors - clinical implications. Curr Cancer Drug Targets. 2018; https://doi.org/10.2174/1568009618666180102103959. This is the recent review describing cisplatin resistance in TGCTs from molecular and clinical viewpoints. It includes information about in vitro and in vivo experimental models that can be used to study this phenomenom CrossRefPubMed

23.

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83. https://doi.org/10.1038/onc.2011.384.CrossRefPubMed

24.

Houldsworth J, Xiao H, Murty VVVS, Chen WY, Ray B, Reuter VE, et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene. 1998;16(18):2345–9. https://doi.org/10.1038/sj.onc.1201770.CrossRefPubMed

25.

di Pietro A, Koster R, Boersma-van Eck W, Dam WA, Mulder NH, Gietema JA, et al. Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. Cell Cycle. 2012;11(24):4552–62. https://doi.org/10.4161/cc.22803.CrossRefPubMedPubMedCentral

26.

Grande L, Bretones G, Rosa-Garrido M, Garrido-Martin EM, Hernandez T, Fraile S, et al. Transcription factors Sp1 and p73 control the expression of the proapoptotic protein Noxa in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem. 2012;287(32):26495–505. https://doi.org/10.1074/jbc.M112.376319.CrossRefPubMedPubMedCentral

27.

Li BZ, Cheng Q, Li ZY, Chen JD. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle. 2010;9(7):1411–20.CrossRefPubMed

28.

Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400–14. https://doi.org/10.1038/nrc2657.CrossRefPubMedPubMedCentral

29.

Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M. Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. P Natl Acad Sci USA. 2011;108(9):3624–9. https://doi.org/10.1073/pnas.1016201108.CrossRef

30.

Noel EE, Yeste-Velasco M, Mao XY, Perry J, Kudahetti SC, Li NF, et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010;176(6):2607–15. https://doi.org/10.2353/ajpath.2010.090780.CrossRefPubMedPubMedCentral

31.

Ajiro M, Katagiri T, Ueda K, Nakagawa H, Fukukawa C, Lin ML, et al. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol. 2009;35(4):673–81.PubMed

32.

Bauer S, Muhlenberg T, Leahy M, Hoiczyk M, Gauler T, Schuler M, et al. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours. Eur Urol. 2010;57(4):679–87. https://doi.org/10.1016/j.eururo.2009.06.014.CrossRefPubMed

33.

• Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2016;34(33):4000–7. https://doi.org/10.1200/JCO.2016.68.7798. This study analyzed a genetic basis for cisplatin resistance by performing whole-exome and targeted sequencing of cisplatin-sensitive and cisplatin-resistant TGCTs. TP53 and MDM2 alterations were associated with cisplatin resistance and inferior outcomes. The presence of actionable genomic alterations in nearly half of cisplatin-resistant TGCTs suggests novel treatment approaches may be of benefit for patients with refractory TGCTs. CrossRefPubMedPubMedCentral

34.

Timmer-Bosscha H, de Vries EG, Meijer C, Oosterhuis JW, Mulder NH. Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line. Cancer Chemother Pharmacol. 1998;41(6):469–76. https://doi.org/10.1007/s002800050769.CrossRefPubMed

35.

Honecker F, Rohlfing T, Harder S, Braig M, Gillis AJ, Glaesener S, et al. Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines. J Proteome. 2014;96:300–13. https://doi.org/10.1016/j.jprot.2013.11.010.CrossRef

36.

Wu G, Scholer HR. Role of Oct4 in the early embryo development. Cell Regen (Lond). 2014;3(1):7. https://doi.org/10.1186/2045-9769-3-7.CrossRef

37.

Abada PB, Howell SB. Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. PLoS One. 2014;9(1):e87444. https://doi.org/10.1371/journal.pone.0087444.CrossRefPubMedPubMedCentral

38.

Koster R, de Jong S. Lessons learned from testicular cancer identification of cytoplasmic p21 as an Achilles’ heel of cisplatin resistance. Cell Cycle. 2010;9(24):4776–7. https://doi.org/10.4161/cc.9.24.14247.CrossRefPubMed

39.

Mueller T, Mueller LP, Holzhausen HJ, Witthuhn R, Albers P, Schmoll HJ. Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. Histochem Cell Biol. 2010;134(2):197–204. https://doi.org/10.1007/s00418-010-0710-1.CrossRefPubMed

40.

Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003;63(9):2244–50.PubMed

41.

Oosterhuis JW, Suurmeyer AJ, Sleyfer DT, Koops HS, Oldhoff J, Fleuren G. Effects of multiple-drug chemotherapy (cis-diammine-dichloroplatinum, bleomycin, and vinblastine) on the maturation of retroperitoneal lymph node metastases of nonseminomatous germ cell tumors of the testis. No evidence for de novo induction of differentiation. Cancer. 1983;51(3):408–16.CrossRefPubMed

42.

Vaughn DJ, Flaherty K, Lal P, Gallagher M, O’Dwyer P, Wilner K, et al. Treatment of growing teratoma syndrome. N Engl J Med. 2009;360(4):423–4. https://doi.org/10.1056/NEJMc0808558.CrossRefPubMed

43.

Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med. 2013;15:e12. https://doi.org/10.1017/erm.2013.13.CrossRefPubMed

44.

Looijenga LH, Gillis AJ, van Gurp RJ, Verkerk AJ, Oosterhuis JW. X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status. Am J Pathol. 1997;151(2):581–90.PubMedPubMedCentral

45.

Wermann H, Stoop H, Gillis AJ, Honecker F, van Gurp RJ, Ammerpohl O, et al. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol. 2010;221(4):433–42. https://doi.org/10.1002/path.2725.CrossRefPubMed

46.

Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, et al. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer. 2004;3:16. https://doi.org/10.1186/1476-4598-3-16.CrossRefPubMedPubMedCentral

47.

Biswal BK, Beyrouthy MJ, Hever-Jardine MP, Armstrong D, Tomlinson CR, Christensen BC, et al. Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. https://doi.org/10.1371/journal.pone.0053003.CrossRefPubMedPubMedCentral

48.

Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, et al. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res. 2009;69(24):9360–6. https://doi.org/10.1158/0008-5472.CAN-09-1490.CrossRefPubMedPubMedCentral

49.

• Albany C, Hever-Jardine MP, von Herrmann KM, Yim CY, Tam J, Warzecha JM et al. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Oncotarget. 2017;8(2):2949–59. doi:https://doi.org/10.18632/oncotarget.13811. This study evaluated the effects of clinically optimized, 2 ^nd generation demethylating agent guadecitabine on embryonal carcinoma cells in vitro and in vivo. These preclinical findings suggest that guadecitabine alone or in combination with cisplatin is a promising strategy to treat refractory TGCTs patients. Effects of gueadecitabine are further studied in an open label proof of concept phase I study (NCT02429466).

50.

Di Vizio D, Cito L, Boccia A, Chieffi P, Insabato L, Pettinato G, et al. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene. 2005;24(11):1882–94. https://doi.org/10.1038/sj.onc.1208368.CrossRefPubMed

51.

Juliachs M, Munoz C, Moutinho CA, Vidal A, Condom E, Esteller M, et al. The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(3):658–67. https://doi.org/10.1158/1078-0432.CCR-13-1131.CrossRef

52.

Mego M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, et al. Phase II study of everolimus in refractory testicular germ cell tumors. Urologic Oncol. 2016;34(3):122–e17–22. https://doi.org/10.1016/j.urolonc.2015.10.010.CrossRef

53.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(10):3384–95. https://doi.org/10.1158/1078-0432.CCR-08-2170.CrossRef

54.

Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, et al. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer. 2012;107(11):1853–63. https://doi.org/10.1038/bjc.2012.481.CrossRefPubMedPubMedCentral

55.

Juliachs M, Vidal A, Del Muro XG, Piulats JM, Condom E, Casanovas O, et al. Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. BMC Cancer. 2013;13:382. https://doi.org/10.1186/1471-2407-13-382.CrossRefPubMedPubMedCentral

56.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6. https://doi.org/10.1056/NEJM197111182852108.CrossRefPubMed

57.

Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer. 1999;85(6):1323–30. https://doi.org/10.1002/(Sici)1097-0142(19990315)85:6<1323::Aid-Cncr15>3.0.Co;2-G.CrossRefPubMed

58.

Bentas W, Beecken WD, Glienke W, Binder J, Schuldes H. Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors. Urol Res. 2003;30(6):390–3. https://doi.org/10.1007/s00240-002-0288-8.CrossRefPubMed

59.

Adam M, Schmidt D, Wardelmann E, Wernert N, Albers P. Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol. 2003;44(3):329–36. https://doi.org/10.1016/S0302-2838(03)00262-8.CrossRefPubMed

60.

Nitzsche B, Gloesenkamp C, Schrader M, Ocker M, Preissner R, Lein M, et al. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Brit J Cancer. 2010;103(1):18–28. https://doi.org/10.1038/sj.bjc.6605725.CrossRefPubMedPubMedCentral

61.

Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014;5:e1327. https://doi.org/10.1038/cddis.2014.270.CrossRefPubMedPubMedCentral

62.

Duale N, Lindeman B, Komada M, Olsen AK, Andreassen A, Soderlund EJ, et al. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Mol Cancer. 2007;6:53. https://doi.org/10.1186/1476-4598-6-53.CrossRefPubMedPubMedCentral

63.

Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124(6):1169–81. https://doi.org/10.1016/j.cell.2006.02.037.CrossRefPubMed

64.

Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, et al. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer. 2011;10:52. https://doi.org/10.1186/1476-4598-10-52.CrossRefPubMedPubMedCentral

65.

Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(13):2129–36. https://doi.org/10.1200/JCO.2008.18.8623.CrossRef

66.

Masque-Soler N, Szczepanowski M, Leuschner I, Vokuhl C, Haag J, Calaminus G, et al. Absence of BRAF mutation in pediatric and adolescent germ cell tumors indicate biological differences to adult tumors. Pediatr Blood Cancer. 2012;59(4):732–5. https://doi.org/10.1002/pbc.24005.CrossRefPubMed

67.

Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie H, Reuter VE, et al. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(14):3712–20. https://doi.org/10.1158/1078-0432.CCR-13-2868.CrossRef

68.

• Piulats JM, Vidal A, Garcia-Rodriguez FJ, Munoz C, Nadal M, Moutinho C et al. Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a re-sensitizing agent. Clin Cancer Research: Off J Am Assoc Cancer Res. 2018. doi:https://doi.org/10.1158/1078-0432.CCR-17-1898. This study reported TGCTs-derived orthoxenografts as preclinical model for the evaluation of the drug efficiency and the identification of markers and gene alterations associated with acquired cisplatin resistance in TGCTs. DL-threo-PDMP, inhibitor of glucosylceramide synthase, was identified as a resensitizing agent in cisplatin-resistant orthoxenografts. CrossRefPubMed

69.

• Selfe J, Goddard NC, McIntyre A, Taylor KR, Renshaw J, Popov SD, et al. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. J Pathol. 2018;244(2):242–53. https://doi.org/10.1002/path.5008. This study identified insulin growth factor receptor-1 as highly expressed and activated in TGCTs cell lines representing the nonseminomatous subtype and also frequently expressed in nonseminoma patient samples. Upregulation of IGF1R expression and signalling was also found to contribute to acquired cisplatin resistance in vitro and its downregulation in the resistant subline resensitized cells to cisplatin CrossRefPubMed

70.

Schaffrath J, Schmoll HJ, Voigt W, Muller LP, Muller-Tidow C, Mueller T. Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS One. 2017;12(6):e0178930. https://doi.org/10.1371/journal.pone.0178930.CrossRefPubMedPubMedCentral

71.

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7. https://doi.org/10.1038/Nm0797-730.CrossRefPubMed

72.

Kozovska Z, Gabrisova V, Kucerova L. Colon cancer: cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother. 2014;68(8):911–6. https://doi.org/10.1016/j.biopha.2014.10.019.CrossRefPubMed

73.

Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH, Chen SS, et al. Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Patho. 2015;8(6):6287–300.

74.

Kulsum S, Sudheendra HV, Pandian R, Ravindra DR, Siddappa G, Nisheena R, et al. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition. Mol Carcinogen. 2017;56(2):694–711. https://doi.org/10.1002/mc.22526.CrossRef

75.

Masters JR, Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003;3(7):517–25. https://doi.org/10.1038/nrc1120.CrossRefPubMed

76.

Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012;22(3):457–72. https://doi.org/10.1038/cr.2012.13.CrossRefPubMedPubMedCentral

77.

Cojoc M, Mabert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015;31:16–27. https://doi.org/10.1016/j.semcancer.2014.06.004.CrossRefPubMed

78.

Barakat SMM, Siar CH. Differential expression of stem cell-like proteins in normal, hyperplastic and dysplastic oral epithelium. J Appl Oral Sci. 2015;23(1):79–86. https://doi.org/10.1590/1678-775720140245.CrossRefPubMedPubMedCentral

79.

• Zhao JH. Cancer stem cells and chemoresistance: the smartest survives the raid. Pharmacol Therapeut. 2016;160:145–58. https://doi.org/10.1016/j.pharmthera.2016.02.008. This review updated the cancer stem cells theories, molecular and cellular mechanisms of their chemoresistance and summarized recent progress in studies on CSC-targeted therapies. The role of ALDH, one of the CSCs markers, is briefly mentioned. CrossRef

80.

Wang Y, Teng JS. Increased multi-drug resistance and reduced apoptosis in osteosarcoma side population cells are crucial factors for tumor recurrence. Exp Ther Med. 2016;12(1):81–6. https://doi.org/10.3892/etm.2016.3303.CrossRefPubMedPubMedCentral

81.

Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PloS One. 2013;8(1) https://doi.org/10.1371/journal.pone.0054193.CrossRefPubMedPubMedCentral

82.

Lu S, Labhasetwar V. Drug-resistant breast cancer cell line displays cancer stem cell phenotype and responds sensitively to epigenetic drug SAHA. Drug Deliv Transl Re. 2013;3(2):183–94. https://doi.org/10.1007/s13346-012-0113-z.CrossRef

83.

Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 2011;10(2):325–35. https://doi.org/10.1158/1535-7163.MCT-10-0788.CrossRefPubMedPubMedCentral

84.

MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, et al. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. Oncotarget. 2017;8(42):72544–63. https://doi.org/10.18632/oncotarget.19881.CrossRefPubMedPubMedCentral

85.

Moreb J, Schweder M, Suresh A, Zucali JR. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther. 1996;3(1):24–30.PubMed

86.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67. https://doi.org/10.1016/j.stem.2007.08.014.CrossRefPubMedPubMedCentral

87.

Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, et al. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. Neoplasma. 2014;61(3):352–62.CrossRefPubMed

88.

Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(12):4234–41. https://doi.org/10.1158/1078-0432.CCR-08-1479.CrossRef

89.

Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Ohta K, et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol. 2013;42(4):1437–42. https://doi.org/10.3892/ijo.2013.1837.CrossRefPubMed

90.

Li T, Su Y, Mei YP, Leng QX, Leng BJ, Liu ZQ, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Investig. 2010;90(2):234–44. https://doi.org/10.1038/labinvest.2009.127.CrossRefPubMed

91.

Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing LX, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7(3):330–8. https://doi.org/10.1158/1541-7786.Mcr-08-0393.CrossRefPubMedPubMedCentral

92.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O’Byrne KJ, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018;428:117–26. https://doi.org/10.1016/j.canlet.2018.04.008.CrossRefPubMed

93.

O’Brien A, Barber JE, Reid S, Niknejad N, Dimitroulakos J. Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3. Anticancer Res. 2012;32(7):2679–88.PubMed

94.

St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, Dimitroulakos J. Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways ana activating transcription factor 3. Neoplasia. 2010;12(7):527–38. https://doi.org/10.1593/neo.92048.CrossRefPubMedPubMedCentral

95.

Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Hartmann JT, et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol. 2011;60(4):850–5. https://doi.org/10.1016/j.eururo.2011.06.019.CrossRefPubMed

96.

S. Schmidtova, K. Kalavska, K. Gercakova, S. Miklikova, E. Durinikova, M. Chovanec, M. Matuskova, M. Mego, L. Kucerova, Inhibition of aldehyde dehydrogenase by disulfiram and poly (ADP-ribose) polymerase by Veliparib reverts cisplatin resistance in germ cell tumor cells, under preparation.

97.

Perry J, Powles T, Shamash J, Veerupillai A, McGrowder E, Noel E, et al. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Cancer Chemother Pharmacol. 2009;64(5):925–33. https://doi.org/10.1007/s00280-009-0944-6.CrossRefPubMed

98.

Reilly PA, Heerema NA, Sledge GW Jr, Palmer CG. Unusual distribution of chromosome 12 in a testicular germ-cell tumor cell line (833K) and its cisplatin-resistant derivative (64CP9). Cancer Genet Cytogenet. 1993;68(2):114–21.CrossRefPubMed

99.

Spierings DC, de Vries EG, Vellenga E, de Jong S. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Cell Death Differ. 2003;10(7):808–22. https://doi.org/10.1038/sj.cdd.4401248.CrossRefPubMed

100.

Timmer-Bosscha H, Timmer A, Meijer C, de Vries EG, de Jong B, Oosterhuis JW, et al. Cis-diamminedichloroplatinum (ii) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res. 1993;53(23):5707–13.PubMed

101.

Curtin JC, Dragnev KH, Sekula D, Christie AJ, Dmitrovsky E, Spinella MJ. Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene. 2001;20(20):2559–69. https://doi.org/10.1038/sj.onc.1204370.CrossRefPubMed

102.

Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res. 1992;52(7):1710–6.PubMed

103.

Walker MC, Povey S, Parrington JM, Riddle PN, Knuechel R, Masters JR. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines. Eur J Cancer. 1990;26(6):742–7.CrossRefPubMed

104.

Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol. 2006;27(2):71–83. https://doi.org/10.1159/000092324.CrossRefPubMed

105.

Casper J, Schmoll HJ, Schnaidt U, Fonatsch C. Cell-lines of human germinal cancer. Int J Androl. 1987;10(1):105–13. https://doi.org/10.1111/j.1365-2605.1987.tb00171.x.CrossRefPubMed

106.

Vogelzang NJ, Bronson D, Savino D, Vessella RL, Fraley EF. A human embryonal-yolk sac carcinoma model system in athymic mice. Cancer. 1985;55(11):2584–93.CrossRefPubMed

107.

Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res. 2003;63(2):513–21.PubMed

Titel: Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors
verfasst von: Silvia Schmidtova
Katarina Kalavska
Lucia Kucerova
Publikationsdatum: 01.11.2018
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 11/2018
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-018-0730-x

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe

Pseudoprogression of Melanoma Brain Metastases

Cancer in Sexual and Gender Minority Patients: Are We Addressing Their Needs?

Palliative Care in Lung Cancer: When to Start

How Intraoperative Tools and Techniques Have Changed the Approach to Brain Tumor Surgery

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie